Sildenafil increases sympathetically mediated vascular tone in humans

American Journal of Hypertension

Volumn 26, Issue 6, 2013, Pages 762-769

  Dopp, John M ^a   Agapitov, Alexei V ^b   Sinkey, Christine A ^b   Haynes, William G ^b   Phillips, Bradley G ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

blood pressure; hypertension; norepinephrine; sildenafil; sympathetic nervous system; vascular tone; vasodilation.

Indexed keywords

ADENOSINE; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; ISOPRENALINE; NORADRENALIN; PHENTOLAMINE; PLACEBO; SILDENAFIL;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FOREARM BLOOD FLOW; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; VASCULAR RESISTANCE; VASOCONSTRICTION;

BLOOD PRESSURE; HYPERTENSION; NOREPINEPHRINE; SILDENAFIL; SYMPATHETIC NERVOUS SYSTEM; VASCULAR TONE; VASODILATION.;

BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; FOREARM; HUMANS; HYPERTENSION; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; REFERENCE VALUES; SULFONES; SYMPATHETIC NERVOUS SYSTEM; VASODILATION;

EID: 84877753251     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt018     Document Type: Article

References (42)

1. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes. A randomized controlled trial. JAMA 1999; 281:421-426.
2. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342:1622-1626.
3. Pfizer. Sildenafil prescribing information. Pfizer: New York, 2010.
4. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8:47-52.
5. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, Bernabé J, Wayman C, Alexandre L, Giuliano FA. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 2008; 53:1272-1280.
6. Rossi R, Nuzzo A, Lattanzi A, Coppi F, Modena MG. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther 2008; 21:172-177.
7. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007; 19:200-207.
8. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: A human in vivo study. Circulation 2005; 111:742-746.
9. Halcox JP, Nour KR, Zalos G, Mincemoyer R, Waclawiw MA, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40:1232-1240.
10. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25:1336-1339.
11. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83:13C- 20C.
12. Kimura M, Yukihito H, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41:1106-1110.
13. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001; 70:270-279.
14. Schalcher C, Schad K, Brunner-La Rocca P, Schindler R, Oechslin E, Scharf C, Suetsch G, Bertel O, Kiowski W. Interaction of sildenafil with camp-mediated vasodilation in vivo. Hypertension 2002; 40:763-767.
15. Konstantinos G and Petros P. Phosphodiesterase-5 inhibitors: Future perspectives. Curr Pharm Des 2009;15:3540-3551.
16. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48:622-627.
17. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50:2136-2144.
18. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, Somers VK. Sympathetic activation by sildenafil. Circulation 2000; 102:3068-3073.
19. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008; 104:1683-1689.
20. Al-Hesayen A, Floras JS, Parker JD. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006; 8:864-868.
21. Haynes WG, Stuchan FE, Webb DJ. Endothelin ETa and ETb receptors mediate vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-363.
22. Hoffman RP, Sinkey CA, Dopp JM, Phillips BG. Systemic and local adrenergic regulation of muscle glucose utilization during hypoglycemia in healthy subjects. Diabetes 2002; 51:734-742.
23. Vobig MA, Klotz T, Staak M, Bartz-Schmidt KU, Engemann U, Walter P. Retinal side effects of sildenafil. Lancet 1999; 353:375.
24. Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother 2002; 36:1129-1134.
25. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75:725-748.
26. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4:8-17.
27. Piccorillo G, Nocco M, Lionetti M, Moise A, Naso C, Marigliano V, Cacciafesta M. Effects of sildenafil citrate (Viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002; 143:703-710.
28. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172:1935-1940.
29. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67:1199-1204.
30. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64:998-1003.
31. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, BPH Registry and Patient Survey Steering Committee. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: Results from the BPH registry. Urology 2009; 73:562-566.
32. Oates HF, Stoker LM, Stokes GS. Interaction between prazosin, clonidine, and direct vasodilators in the anaesthetized rat. Clin Exp Pharm Physiol 1978; 5:85-89.
33. Leenen FH, Burns RJ, Myers MG, Frankel D. Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. Cardiovasc Drugs Ther 1990; 4:499-504.
34. Donnelly R, Elliott HL, Meredith PA, Howie CA, Reid JL. Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992; 19:479-486.
35. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157.
36. Faber JE, Szymeczek CL, Cotecchia S, Thomas SA, Tanoue A, Tsujimoto G, Zhang H. α1-Adrenoreceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2007; 292:H2316-H2323.
37. Erami C, Zhang H, Ho JG, French DM, Faber JE. ?1-Adrenoreceptor stimulation directly induces growth of the injured vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002; 283:H1577-H1587.
38. Zhang H, Facemire C, Banes AJ, Faber JE. Different alpha-adrenoreceptors mediate migration of vascular smooth muscle cells and adventitial fibroblasts in vitro. Am J Physiol Heart Circ Physiol 2002; 282:H2364-H2370.
39. Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G. Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 2002; 105:1700-1707.
40. Faber JE, Yang N, Xin X. Expression of ?-adrenoreceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther 2001; 298:441-452.
41. Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ, Super-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. Chest 2011; 140: 1274-1283.
42. Agapitov AV, Correia ML, Sinkey CA, Haynes WG. Dissociation between sympathetic nerve traffic and sympathetically-mediated vascular tone in normotensive human obesity. Hypertension 2008; 52: 687-695.